Faten Farouk1, Dina Wahba2, Sherif Mogawer3, Shaimaa Elkholy3, Ahmed Elmeligui3, Reham Abdelghani4, Salwa Ibahim4. 1. Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, 6th October City, Egypt. f.farouk04@gmail.com. 2. National Organization of Drug Quality Control and Research, Giza, Egypt. 3. Internal Medicine Department, Hepato-gastroenterology Unit, Faculty of Medicine, Cairo University, Giza, Egypt. 4. Internal Medicine Department, Nephrology Unit, Faculty of Medicine, Cairo University, Giza, Egypt.
Abstract
BACKGROUND AND OBJECTIVE: The effectiveness of direct-acting antivirals (DAAs) is not well established in end-stage renal disease (ESRD) patients. Assessment of the plasma concentrations may support understanding of their therapeutic outcomes in this population. The aim of this study is to develop a direct, yet matrix-effect tolerant, analytical method for determining DAAs in the plasma of ESRD patients while maintaining a moderate cost per sample and with an improved analyte extraction recovery. METHODS: In this study, a liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed for the analysis of ombitasvir (OMB), paritaprevir (PRT) and ritonavir (RIT) in plasma. Sample preparation was performed using the liquid-liquid extraction (LLE) method. Isocratic separation was performed using a mixture of methanol and 10 mM ammonium acetate (79:21, v/v) followed by MS/MS detection. The method was validated and applied to determine DAAs in the plasma of ESRD patients (n = 7). RESULTS: The developed method was linear (r2 > 0.995), accurate (89.4 ± 7.8 to 108.3 ± 3.0) and precise (% CV 0.9-15.0) and showed improved recovery (> 80) over previously published ones in the range 5-250, 30-1,500, 20-1,000 ng/mL for OMB, PRT and RIT, respectively. Relative matrix effect was absent, and the method accurately determined the three DAAs in real-life samples (n = 7). CONCLUSIONS: An efficient analytical method for the determination of DAAs is presented. The method overcomes the potential analytical response fluctuation in ESRD. The developed method show improved extraction recoveries and is suitable for routine application in developing economies where hepatitis C virus is most prevalent.
BACKGROUND AND OBJECTIVE: The effectiveness of direct-acting antivirals (DAAs) is not well established in end-stage renal disease (ESRD) patients. Assessment of the plasma concentrations may support understanding of their therapeutic outcomes in this population. The aim of this study is to develop a direct, yet matrix-effect tolerant, analytical method for determining DAAs in the plasma of ESRDpatients while maintaining a moderate cost per sample and with an improved analyte extraction recovery. METHODS: In this study, a liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed for the analysis of ombitasvir (OMB), paritaprevir (PRT) and ritonavir (RIT) in plasma. Sample preparation was performed using the liquid-liquid extraction (LLE) method. Isocratic separation was performed using a mixture of methanol and 10 mM ammonium acetate (79:21, v/v) followed by MS/MS detection. The method was validated and applied to determine DAAs in the plasma of ESRDpatients (n = 7). RESULTS: The developed method was linear (r2 > 0.995), accurate (89.4 ± 7.8 to 108.3 ± 3.0) and precise (% CV 0.9-15.0) and showed improved recovery (> 80) over previously published ones in the range 5-250, 30-1,500, 20-1,000 ng/mL for OMB, PRT and RIT, respectively. Relative matrix effect was absent, and the method accurately determined the three DAAs in real-life samples (n = 7). CONCLUSIONS: An efficient analytical method for the determination of DAAs is presented. The method overcomes the potential analytical response fluctuation in ESRD. The developed method show improved extraction recoveries and is suitable for routine application in developing economies where hepatitis C virus is most prevalent.
Authors: J Durant; P Clevenbergh; R Garraffo; P Halfon; S Icard; P Del Giudice; N Montagne; J M Schapiro; P Dellamonica Journal: AIDS Date: 2000-07-07 Impact factor: 4.177
Authors: R H Haubrich; S J Little; J S Currier; D N Forthal; C A Kemper; G N Beall; D Johnson; M P Dubé; J Y Hwang; J A McCutchan Journal: AIDS Date: 1999-06-18 Impact factor: 4.177
Authors: Shoshana H Ballew; Yan Chen; Natalie R Daya; Job G Godino; B Gwen Windham; Mara McAdams-DeMarco; Josef Coresh; Elizabeth Selvin; Morgan E Grams Journal: Am J Kidney Dis Date: 2016-11-22 Impact factor: 8.860
Authors: Maria A Acquavia; Luca Foti; Raffaella Pascale; Antonia Nicolò; Vincenzo Brancaleone; Tommaso R I Cataldi; Giuseppe Martelli; Laura Scrano; Giuliana Bianco Journal: Talanta Date: 2020-11-05 Impact factor: 6.057